Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

AISN Integrating AI in Stroke Neurorehabilitation

Coordinator
Universidad Miguel Hernandez De Elche, Spain
Runs
1 December 2022 to 30 June 2027
Status
Running
EU funding
€5.9m
Total cost
€6.0m
Partners
18 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101057655

What the project is doing

In the project's own words, from its summary on CORDIS.

Health services are increasingly moving towards a treatment continuum aligned with the patient journey. This transition will critically depend on the successful deployment of trustworthy AI-enhanced technologies that are accurate, secure, and trusted. The AISN project will develop and validate operating procedures and guidelines for integrating AI in a healthcare continuum, focussing on post-stroke rehabilitation. AISN delivers a representative AI health platform built from integrating validated platforms for data acquisition and access, clinical interpretation, whole-brain simulation, clinically validated intervention delivery and optimization and model-based prediction.

The AISN integrated platform will be validated in the clinical context of rehabilitation in the outpatient and at-home phase and facilitate a concrete assessment of the fundamental ways in which AI-enhanced clinical decision-support will change the care pathway and the formulation of novel AI compatible treatment guidelines. AISN ensures an ethical approach by developing legal and ethical guidelines for the robust, fair, and trustworthy deployment of AI in health and validating acceptance and transparency of its solutions.

Building on the AISN platform, the project will test current standard operating procedures for integrating AI in health care and formulate and validate new ones where needed. The AISN guidelines and procedures will emphasize the evidence base and safety of clinical interventions, transparency, prognostics at varying time-scales, personalization of interventions, access to disease-specific information by clinicians, patients and their carers, and assure that the potential of AI is fully developed in the service of value-based medicine satisfying standards of security and safety.

We will go beyond currently available guidelines and frameworks by emphasizing explainability, AI tools with evolving performance, and the dynamic interaction between users and algorithms.

Topics

Who is involved

OrganisationCityCountryRole
Universidad Miguel Hernandez De ElcheElcheSpainCoordinator
Universitat WienWienAustriaParticipant
EbrainsBruxelles / BrusselBelgiumParticipant
Insel Gruppe AGBernSwitzerlandAssociatedpartner
Les Hopitaux Universitaires De GeneveGeneve 14SwitzerlandAssociatedpartner
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Tp21 GmbHBerlinGermanyParticipant
Eodyne Systems SLBarcelonaSpainParticipant
Fundacio Privada per a La Recerca I La Docencia Sant Joan De DeuEsplugues De LlobregatSpainParticipant
Medtronic Iberica SAMadridSpainParticipant
Parc Sanitari Sant Joan De DeuSant Boi De LlobregatSpainThird party
Centre hospitalier universitaire de LimogesLimogesFranceParticipant
Universite De LimogesLimogesFranceParticipant
San Camillo Irccs SRLVeneziaItalyParticipant
Saddle Point Science Europe BVNijmegenNetherlandsParticipant
Stichting Radboud UniversiteitNijmegenNetherlandsParticipant
Universitatea De Medicina Si Farmacie Iuliu Hatieganu Cluj-NapocaCluj-NapocaRomaniaParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI